| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Islam Hany Gamaleddin, Jose M Trigo, Aliou B Gueye, Alexander Zvonok, Alexandros Makriyannis, Steven R Goldberg, Bernard Le Fol. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Frontiers in psychiatry. vol 6. 2015-04-10. PMID:25859226. |
the cb1 receptor inverse agonist/antagonist rimonabant (also known as sr141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. |
2015-04-10 |
2023-08-13 |
human |
| Miriam Melis, Marco Pisti. Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives. Pharmacological research. vol 86. 2015-03-30. PMID:24704146. |
nicotine's strong addicting properties reside in its ability to enhance dopamine transmission, and to induce specific changes in synaptic plasticity. |
2015-03-30 |
2023-08-13 |
Not clear |
| Serge Guerreiro, Clélia Florence, Erwann Rousseau, Sabah Hamadat, Etienne C Hirsch, Patrick P Miche. The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. Molecular pharmacology. vol 87. issue 3. 2015-03-20. PMID:25552485. |
the sleep-modulating peptide orexin-b protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. |
2015-03-20 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
however, recent reports showed that long-term nicotine exposure itself also decreases accumbal dopamine release, suggesting that additional mechanisms are involved in withdrawal. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
here, we used real-time cyclic voltammetry in brain slices containing the nucleus accumbens to further elucidate the changes in dopamine release linked to nicotine withdrawal. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
subsequent voltammetry studies showed that long-term nicotine decreased single-pulse-stimulated dopamine release via an interaction at α6β2* receptors. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
in addition, long-term nicotine treatment alone increased dopamine release paired-pulse ratios and this was partially reversed with nicotine removal. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
we then evaluated the effect of bath-applied nicotine and varenicline on dopamine release. |
2015-02-18 |
2023-08-13 |
rat |
| Xiomara A Perez, Taline V Khroyan, J Michael McIntosh, Maryka Qui. Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacology research & perspectives. vol 3. issue 1. 2015-02-18. PMID:25692023. |
altogether these data suggest that nicotine withdrawal is associated with a partial restoration of dopamine release measures to control levels and that varenicline's differential modulation of dopamine release may contribute to its mechanism of action. |
2015-02-18 |
2023-08-13 |
rat |
| Aryeh I Herman, Elise E DeVito, Kevin P Jensen, Mehmet Sofuogl. Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics. vol 15. issue 2. 2015-02-12. PMID:24444411. |
pharmacogenetics of nicotine addiction: role of dopamine. |
2015-02-12 |
2023-08-12 |
Not clear |
| Aryeh I Herman, Elise E DeVito, Kevin P Jensen, Mehmet Sofuogl. Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics. vol 15. issue 2. 2015-02-12. PMID:24444411. |
the neurotransmitter dopamine (da) plays a central role in addictive disorders, including nicotine addiction. |
2015-02-12 |
2023-08-12 |
Not clear |
| Tanuja Bordia, Matthew McGregor, Roger L Papke, Michael W Decker, J Michael McIntosh, Maryka Qui. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Experimental neurology. vol 263. 2015-02-09. PMID:25261754. |
abt-107 and nicotine also significantly improved basal dopamine release from lesioned striatum, as well as nicotine-stimulated dopamine release mediated via α4β2* and α6β2* nachrs. |
2015-02-09 |
2023-08-13 |
rat |
| Michelle S Mazei-Robison, Raghu Appasani, Scott Edwards, Sunmee Wee, Seth R Taylor, Marina R Picciotto, George F Koob, Eric J Nestle. Self-administration of ethanol, cocaine, or nicotine does not decrease the soma size of ventral tegmental area dopamine neurons. PloS one. vol 9. issue 4. 2015-01-20. PMID:24755634. |
self-administration of ethanol, cocaine, or nicotine does not decrease the soma size of ventral tegmental area dopamine neurons. |
2015-01-20 |
2023-08-13 |
mouse |
| Susanne Jonsson, Louise Adermark, Mia Ericson, Bo Söderpal. The involvement of accumbal glycine receptors in the dopamine-elevating effects of addictive drugs. Neuropharmacology. vol 82. 2015-01-09. PMID:24686030. |
these data indicate that accumbal glyrs play a key role in ethanol-induced dopamine activation and contribute also to that of cannabinoids and nicotine. |
2015-01-09 |
2023-08-12 |
rat |
| Munir G Kutlu, Dennis Burke, Susan Slade, Brandon J Hall, Jed E Rose, Edward D Levi. Role of insular cortex D₁ and D₂ dopamine receptors in nicotine self-administration in rats. Behavioural brain research. vol 256. 2014-12-18. PMID:23948214. |
role of insular cortex d₁ and d₂ dopamine receptors in nicotine self-administration in rats. |
2014-12-18 |
2023-08-12 |
rat |
| Yu-Jun Wang, Peng Huang, Julie A Blendy, Lee-Yuan Liu-Che. Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G. Addiction biology. vol 19. issue 3. 2014-12-16. PMID:22862850. |
the a118g single nucleotide polymorphism (snp) of the human μ-opioid receptor (mopr) gene (oprm1) was associated with heightened dopamine release by alcohol intake, better treatment outcome for nicotine and alcohol addiction, and reduced analgesic responses to morphine. |
2014-12-16 |
2023-08-12 |
mouse |
| Joanna Jastrzębska, Ewa Nowak, Irena Smaga, Beata Bystrowska, Małgorzata Frankowska, Michael Bader, Małgorzata Filip, Kjell Fux. Adenosine (A)(2A)receptor modulation of nicotine-induced locomotor sensitization. A pharmacological and transgenic approach. Neuropharmacology. vol 81. 2014-12-15. PMID:24632528. |
changes in the levels of dopamine, glutamate and γ-aminobutyric acid in wild type (wt) and nsea(2a) rats were determined with using lc-ms. kw 6002 significantly enhanced expression of nicotine sensitization and conditioned locomotion, while cgs 21680 reduced all these effects in wt rats. |
2014-12-15 |
2023-08-12 |
rat |
| Kristen M Mackowick, Mera S Barr, Victoria C Wing, Rachel A Rabin, Clairelaine Ouellet-Plamondon, Tony P Georg. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:23871750. |
pre-clinical evidence has shown that nicotine affects several neurotransmitter systems, including dopamine (da), glutamate, and γ-aminobutyric acid (gaba), and certain neuropsychological deficits associated with these neurotransmitters (reaction time, spatial working memory, sustained attention, and sensory gating) are improved after nicotine administration in patients with schizophrenia. |
2014-12-12 |
2023-08-12 |
Not clear |
| Scott H Kollins, R Alison Adcoc. ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence. Progress in neuro-psychopharmacology & biological psychiatry. vol 52. 2014-12-12. PMID:24560930. |
adhd, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence. |
2014-12-12 |
2023-08-12 |
Not clear |